Company profilePharmaceutical#517 of 1,318 in Pakistan✓ No DRAP alerts

Zamko Pharmaceuticals (Pvt) Ltd.

Pharmaceutical company · 26 brands · 26 molecules

Ranked #199 of 207 companies in Quinolone Antibacterials

26 registered products 22 pharmaceutical brands 26 distinct molecules 0 DRAP alerts

Company overview

26
registered products
22
pharmaceutical brands
26
distinct molecules
2
therapeutic classes
0
DRAP alerts

Zamko Pharmaceuticals (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 26 product registrations across 26 distinct molecules. Its portfolio is concentrated in Quinolone Antibacterials and Antimycotics Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Zamko

17 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

17
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202517

Top molecules by brand count

Azithromycin3 brands
Linezolid2 brands
Levofloxacin2 brands
Omeprazole2 brands
Moxifloxacin2 brands
Fluconazole2 brands
Itraconazole ...... 100 Mg1 brand
Moxifloxacin ...... 400 Mg1 brand

Therapeutic classes

Quinolone Antibacterials · 1Antimycotics Systemic Use · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official34 products · Rs 128.7 – Rs 5,030.41
Median across source: Rs 565.82

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

HIGH - Q INTERNATIONAL16 shared molecules
MEDISAVE PHARMACEUTICALS16 shared molecules
BIO LABS (PVT) LTD.14 shared molecules
PEARL PHARMACEUTICALS14 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Winlet Pharmaceuticals (Pvt) Ltd. holds 51 molecules not in this portfolio
000 I.UAcyclovirAmlodipineArtemetherCefiximeCeftriaxone
HIGH - Q INTERNATIONAL holds 134 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmikacinAmlodipineAnastrozoleAprepitant
GENOME PHARMACEUTICALS (PVT) LTD holds 107 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtemether

Get the full profile for Zamko

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.